Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The move to Research Triangle Park follows Immunovia’s model development study and completion of the discovery phase for its next-generation test in November 2023. Following these developments, the company will focus ..read more

About half of the 26 employees were made redundant prior to the bankruptcy and the other half have had their employment agreements terminated following the bankruptcy. As things stand, most of the members of the leadership team are available for a short period of time to ensure compliance with applicable regulatory requirements and to assist ..read more

The company has announced the successful closure of an oversubscribed bridge financing round. Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders. The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis ..read more

Recently, the annual Entrepreneur’s Gala took place at Uppsala Castle to honor companies that showed exceptional performance during the past year and the Entrepreneur of the Year award was awarded to Ulrika Hammarström, CEO and Founder of Scandinavian CRO (SCRO). This prize is awarded by jury to an entrepreneur who has performed above and beyond ..read more

Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of ..read more

In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs, and others to a femtech innovation hackathon, a hackaton focused on reducing the gender health gap and advancing women’s health. Initiators of the hackaton were ..read more

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I ..read more

Boston’s Kendall Square, close to Massachusetts Institute of Technology (MIT), is known as “The most innovative square mile on the planet” and, apart from our preference for the metric system, there just might be something we could learn from the Americans. One of the recommendations is that public and private stakeholders, inspired by the success ..read more

Ultimovacs has announced a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several cancer indications and immunotherapy combinations, and we are prepared for both challenges and accomplishments along the way. We anticipate ..read more

Sound Bioventures participated in the financing round, which raised a total of USD 24.5 million, and joins an existing investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford. In conjunction with this financing, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors. Read more ..read more